Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 11/20 | 0.65 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.42 |
| ▸ | MAP2K4 | P45985 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.38 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9104476 | 0.89 | HTR5A (0.51) | HTR5AMAP2K4MAPTPARP1ALDH1A1 | |
| SCHEMBL9907515 | 0.86 | HTR5A (0.67) | HTR5ACSNK2A1MAP2K4MEN1MAPT | |
| SCHEMBL9907672 | 0.85 | HTR5A (0.71) | HTR5ACSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL9907691 | 0.83 | HTR5A (0.60) | HTR5ACSNK2A1 | |
| SCHEMBL9907686 | 0.83 | HTR5A (0.60) | HTR5ACSNK2A1MEN1MAPTCASP3 | |
| SCHEMBL9907637 | 0.82 | HTR5A (0.66) | HTR5AMAPT | |
| SCHEMBL9907704 | 0.82 | CSNK2A2 (0.54) | HTR5ACSNK2A1MAP2K4MEN1MAPT | |
| SCHEMBL9907703 | 0.81 | MAP2K4 (0.54) | HTR5AMAP2K4MEN1MAPTKMT2A | |
| SCHEMBL12874614 | 0.81 | HTR5A (0.54) | HTR5AMAP2K4MEN1MAPTKMT2A | |
| SCHEMBL9907692 | 0.81 | HTR5A (0.55) | HTR5ACSNK2A1MAP2K4MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | HTR5A 1/4885CSNK2A1 4309/4885MAP2K4 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.